Semliki Forest virus vectors expressing the H and HN genes of measles and mumps viruses reduce immunity induced by the envelope protein genes of rubella virus

Vaccine

Volumn 25, Issue 43, 2007, Pages 7481-7490

  Callagy, Sara J ^a   Kelly, Barbara J ^a   Fleeton, Marina N ^a   Sheahan, Brian J ^b   Galbraith, Sareen E ^a,b,c   Atkins, Gregory J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Multivalent vaccines; Rubella virus; Semliki Forest virus vector

Indexed keywords

BLOOD GROUP H ANTIGEN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HN PROTEIN; MEASLES MUMPS RUBELLA VACCINE; SEMLIKI FOREST VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNITY; LATEX AGGLUTINATION TEST; MEASLES; MEASLES VIRUS; MOUSE; MUMPS; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RUBELLA VIRUS; SEMLIKI FOREST ALPHAVIRUS; VACCINATION; VIRUS TITRATION;

AGGLUTINATION TESTS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MUMPS VIRUS; RUBELLA VIRUS; SEMLIKI FOREST VIRUS; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 34848924309     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.049     Document Type: Article

References (30)

1. Atkins G.J., and Cosby S.L. Is an improved measles-mumps-rubella vaccine necessary or feasible?. Crit Rev Immunol 23 4 (2003) 323-338
2. Pougatcheva S.O., Abernathy E.S., Vzorov A.N., Compans R.W., and Frey T.K. Development of a rubella virus DNA vaccine. Vaccine 17 15-16 (1999) 2104-2112
3. Jefferson T., Price D., Demicheli V., and Bianco E. Unintended events following immunization with MMR: a systematic review. Vaccine 21 25-26 (2003) 3954-3960
4. Shingai M., Inoue N., Okuno T., Okabe M., Akazawa T., Miyamoto Y., et al. Wild-type measles virus infection in human CD46/CD150-transgenic mice: CD11c-positive dendritic cells establish systemic viral infection. J Immunol 175 5 (2005) 3252-3261
5. Moss W.J., Ota M.O., and Griffin D.E. Measles: immune suppression and immune responses. Int J Biochem Cell Biol 36 8 (2004) 1380-1385
6. Lundstrom K. Alphavirus-based vaccines. Curr Opin Mol Ther 4 1 (2002) 28-34
7. Glasgow G.M., McGee M.M., Sheahan B.J., and Atkins G.J. Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol 78 7 (1997) 1559-1563
8. Glasgow G.M., McGee M.M., Tarbatt C.J., Mooney D.A., Sheahan B.J., and Atkins G.J. The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol 79 10 (1998) 2405-2410
9. Morris-Downes M.M., Sheahan B.J., Fleeton M.N., Liljestrom P., Reid H.W., and Atkins G.J. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. Vaccine 19 28-29 (2001) 3877-3884
10. Fleeton M.N., Liljestrom P., Sheahan B.J., and Atkins G.J. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 81 3 (2000) 749-758
11. Hanke T., Barnfield C., Wee E.G., Agren L., Samuel R., Larke N., et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84 2 (2003) 361-368
12. Berglund P., Fleeton M.N., Smerdou C., and Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17 5 (1999) 497-507
13. Pugachev K.V., Abernathy E.S., and Frey T.K. Genomic sequence of the RA27/3 vaccine strain of rubella virus. Arch Virol 142 6 (1997) 1165-1180
14. Perrenoud G., Messerli F., Thierry A.C., Beltraminelli N., Cousin P., Fasel N., et al. A recombinant rubella virus E1 glycoprotein as a rubella vaccine candidate. Vaccine 23 4 (2004) 480-488
15. Cusi M.G., Fischer S., Sedlmeier R., Valissina M., Valensin P.E., Donati M., et al. Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. Virus Res 74 1-2 (2001) 133-137
16. Pan C.H., Valsamakis A., Colella T., Nair N., Adams R.J., Polack F.P., et al. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. PNAS 102 33 (2005) 11581-11588
17. Chaye H.H., Mauracher C.A., Tingle A.J., and Gilliam S. Cellular and humoral immune responses to rubella virus structural proteins E1, E2, and C. J Clin Microbiol 30 9 (1992) 2323-2329
18. Suomalainen M.H., Garoff H., and Baron M.D. The E2 signal sequence of rubella virus remains part of the capsid protein and confers membrane association in vitro. J Virol 64 11 (1990) 5500-5509
19. Nakhasi H.L., Thomas D., Zheng D.X., and Liu T.Y. Nucleotide sequence of capsid, E2 and E1 protein genes of rubella virus vaccine strain RA27/3. Nucleic Acids Res 17 11 (1989) 4393-4394
20. Karounos D.G., Wolinsky J.S., and Thomas J.W. Monoclonal antibody to rubella virus capsid protein recognizes a beta-cell antigen. J Immunol 150 7 (1993) 3080-3085
21. Smerdou C.L., and Lilijestrom P. Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 73 2 (1999) 1092-1098
22. Chikkanna-Gowda C.P., Sheahan B.J., Fleeton M.N., and Atkins G.J. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12 16 (2005) 1253-1263
23. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 25 7 (2004) 381-386
24. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptove immune responses. Nat Immunol 5 10 (2004) 987-995
25. Fleeton M.N., Chen M., Berglund P., Rhodes G., Parker S.E., Murphy M., et al. Self-replicative RNA vaccines elicit protection against influenza a virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183 9 (2001) 1395-1398
26. Morris-Downes M.M., Phenix K.V., Smyth J., Sheahan B.J., Liljeqvist S., Mooney D.A., et al. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19 15-16 (2001) 1978-1988
27. Nilsson C., Makilato B., Berglund P., Bex F., Liljestrom P., Sutter G., et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19 25-26 (2001) 3526-3536
28. Song M.K., Vindurampulle C.J., Capozzo A.V., Ulmer J., Polo J.M., Pasetti M.F., et al. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol 79 15 (2005) 9854-9861
29. Heaney J., Barrett T., and Cosby S.L. Inhibition of in vitro leukocyte proliferation by morbilliviruses. J Virol 76 7 (2002) 3579-3584
30. Kedl R.M., Kappler J.W., and Manack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 15 1 (2003) 120-127